Abstract：Objective To investigate the prognostic results of clinicopathological data in patients with colorectal cancer combined with ascites and analyze the prognosis. Methods The clinicopathological and follow up study data of 139 patients combined with ascites and 400 patients without ascites between October 1999 and January 2005 in our department were retrospectively analyzed and evaluated the prognosis between them by SPSS 19.0. Results Single factor analysis revealed that the prognostic of patients combined with ascites were associated with the factors,such as intestinal obstruction,pelvic metastatic nodal,peritoneal implantation,liver metastasis,viscera invasion,tumor location,radical degrees,tumor type,depth of infiltration,and histological classification（P＜0.01）.Peritoneal implantation（OR＝1.781,95％CI＝1.131-2.804）,pelvic metastatic nodal（OR＝3.211,95％CI＝1.196-8.623）,liver metastasis（OR＝3.127,95％CI＝1.777-5.502）,depth of infiltration（OR＝2.789,95％CI＝1.015-7.665）were of important factors in radical prostatectomy of colorectal cancer combined with ascites by binary Logistic analysis;survival analysis revealed that overall survival were different in whether colorectal cancer combined with ascites（1,3,5,10 year of survival rate respectively:80％,67％,60％, 41％vs 58％,48％,38％,27％）and resection and lymphnodenectomy contribute to improve overall survival（P＜0.05）. Conclusion Patients with colorectal cancer combined with ascites indicate poor prognostic results.Patients with colorectal cancer combined with ascites underwent dissection and lymphnodenectomy can significantly improve the survival rates.
王红旭;张继东;李东平;陆艳兴;李睿. 结直肠癌同时合并腹水的临床病理特点及其预后分析[J]. 中国当代医药, 2016, 23(2): 42-46.
WANG Hong-xu;ZHANG Ji-dong;LI Dong-ping;LU Yan-xing;LI Rui. Clinicopathological features and prognosis of colorectal cancer with ascites. 中国当代医药, 2016, 23(2): 42-46.
Garrison RN，Galloway RH，Heuser LS.Mechanisms of malignant ascites production[J].J Surg Res，1987，42（8）：126-132.
[5]
Olopade OI，Ultmann JE.Malignant effusions[J].CA Cancer J Clin，1991，41（3）：166-179.
[1]
Lu J，Li XF，Kong LX，et al.Expression and significance of cyclooxygenase-2 mRNA in benign and malignant ascites[J]. World J Gastroenterol，2013，19（40）：6883-6887.
Tamura S，Miki H，Okada K，et al.Pilot study of a combination of S1and paclitaxel for patients with peritoneal metastasis from gastric cancer[J].Gastric Cancer，2010，13 （2）：101-108.
[9]
Kobayashi M，Sakamoto J，Namikawa T，et al.Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients[J].World J Gastroenterol，2006，12（12）：1412-1415.
[10]
Yamao T，Shimada Y，Shirao K，et al.PhaseⅡstudy of sequential methotrexate and 5-Fluorouracil chemothera-py against peritoneally disseminated gastric cancer with malignant ascites：a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group，JCOG 9603 Trail[J].Jpn J Clin Oncol，2004，34（32）：316-322.
[11]
Tahara M，Ohtsu A，Boku N，et al.Sequential methotrexate and 5-Fluorouracil therapy for gastric cancer patients with peritoneal dissemination：a retrospective study [J]. Gastric Cancer，2001，4（9）：212-218.
[12]
Haruhiko I，Koji O，Junichi S，et al.Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions：a multicenter phase Ⅱtrial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer[J].Gastric Cancer，2011，14（7）：81-90.
[13]
Masako I，Takashi K，Narikazu B，et al.Efficacy of sequential methotrexate and 5-Fluorouracil（MTX/5FU）in improving oral intake in patients with advanced gastric cancer with[J].Gastric Cancer，2009，12（8）：153-157.
Cui S，Ba M，Tang Y，et al.Bultrasound-guided hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites[J].Oncol Rep，2012，28（4）：1325-1331.
京公网安备 11010502046607号